IL313939B2 - נוגדי אנטי pd-1 לטיפול בגידולים בחולים בעלי עומס גידול מוטציוני גבוה (tmb) - Google Patents

נוגדי אנטי pd-1 לטיפול בגידולים בחולים בעלי עומס גידול מוטציוני גבוה (tmb)

Info

Publication number
IL313939B2
IL313939B2 IL313939A IL31393924A IL313939B2 IL 313939 B2 IL313939 B2 IL 313939B2 IL 313939 A IL313939 A IL 313939A IL 31393924 A IL31393924 A IL 31393924A IL 313939 B2 IL313939 B2 IL 313939B2
Authority
IL
Israel
Prior art keywords
tmb
antibodies
patients
treating tumors
high tumor
Prior art date
Application number
IL313939A
Other languages
English (en)
Other versions
IL313939A (he
IL313939B1 (he
Inventor
Han Chang
Prabhu Seshaiyer Bhagavatheeswaran
Nicholas Allan John Botwood
Yali Fu
William J Geese
George A Green Iv
Diane Healey
Sabine Maier
Faith E Nathan
Abderrahim Oukessou
Giovanni Selvaggi
Joseph Daniel Szustakowski
Original Assignee
Bristol Myers Squibb Co
Han Chang
Prabhu Seshaiyer Bhagavatheeswaran
Nicholas Allan John Botwood
Yali Fu
William J Geese
George A Green Iv
Diane Healey
Sabine Maier
Faith E Nathan
Abderrahim Oukessou
Giovanni Selvaggi
Joseph Daniel Szustakowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Han Chang, Prabhu Seshaiyer Bhagavatheeswaran, Nicholas Allan John Botwood, Yali Fu, William J Geese, George A Green Iv, Diane Healey, Sabine Maier, Faith E Nathan, Abderrahim Oukessou, Giovanni Selvaggi, Joseph Daniel Szustakowski filed Critical Bristol Myers Squibb Co
Publication of IL313939A publication Critical patent/IL313939A/he
Publication of IL313939B1 publication Critical patent/IL313939B1/he
Publication of IL313939B2 publication Critical patent/IL313939B2/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
IL313939A 2017-03-31 2018-03-30 נוגדי אנטי pd-1 לטיפול בגידולים בחולים בעלי עומס גידול מוטציוני גבוה (tmb) IL313939B2 (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479817P 2017-03-31 2017-03-31
US201762582146P 2017-11-06 2017-11-06
PCT/US2018/025518 WO2018183928A1 (en) 2017-03-31 2018-03-30 Methods of treating tumor

Publications (3)

Publication Number Publication Date
IL313939A IL313939A (he) 2024-08-01
IL313939B1 IL313939B1 (he) 2026-01-01
IL313939B2 true IL313939B2 (he) 2026-05-01

Family

ID=62067782

Family Applications (3)

Application Number Title Priority Date Filing Date
IL313939A IL313939B2 (he) 2017-03-31 2018-03-30 נוגדי אנטי pd-1 לטיפול בגידולים בחולים בעלי עומס גידול מוטציוני גבוה (tmb)
IL269026A IL269026B2 (he) 2017-03-31 2018-03-30 נוגדי אנטי pd-1 לטיפול בגידולים בחולים בעלי עומס גידול מוטציוני גבוה (tmb)
IL325195A IL325195A (he) 2017-03-31 2018-03-30 נוגדי אנטי pd-1 לטיפול בגידולים בחולים בעלי עומס גידול מוטציוני גבוה (tmb)

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL269026A IL269026B2 (he) 2017-03-31 2018-03-30 נוגדי אנטי pd-1 לטיפול בגידולים בחולים בעלי עומס גידול מוטציוני גבוה (tmb)
IL325195A IL325195A (he) 2017-03-31 2018-03-30 נוגדי אנטי pd-1 לטיפול בגידולים בחולים בעלי עומס גידול מוטציוני גבוה (tmb)

Country Status (13)

Country Link
US (3) US20210101980A1 (he)
EP (1) EP3601355A1 (he)
JP (2) JP7458188B2 (he)
KR (2) KR20250036268A (he)
CN (1) CN110494450A (he)
AU (2) AU2018243754B2 (he)
BR (1) BR112019019795A2 (he)
CA (1) CA3058175A1 (he)
IL (3) IL313939B2 (he)
MA (1) MA50056A (he)
MX (2) MX2019010958A (he)
SG (2) SG11201908396PA (he)
WO (1) WO2018183928A1 (he)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2016176504A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JP2018514550A (ja) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
WO2019075468A1 (en) * 2017-10-15 2019-04-18 Bristol-Myers Squibb Company TUMOR TREATMENT METHODS
CA3093407A1 (en) * 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020022791A1 (ko) 2018-07-25 2020-01-30 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
EP3857555B1 (en) * 2018-10-17 2026-04-01 Tempus AI, Inc. Data based cancer research and treatment systems and methods
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
KR20210081384A (ko) 2018-10-23 2021-07-01 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
EP3880246A4 (en) * 2018-11-15 2022-08-10 Personal Genome Diagnostics Inc. METHODS TO IMPROVE RESPONSE PREDICTION IN IMMUNOTHERAPY-TREATED CANCER PATIENTS
CN113194995A (zh) * 2018-12-12 2021-07-30 免疫医疗有限责任公司 基于血液的肿瘤突变负荷预测非小细胞肺癌的总存活
CN113228190B (zh) * 2018-12-23 2024-06-11 豪夫迈·罗氏有限公司 分类和/或鉴定癌症亚型的系统和方法
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
US20220195046A1 (en) * 2019-03-28 2022-06-23 Bristol-Myers Squibb Company Methods of treating tumor
GB201904555D0 (en) * 2019-04-01 2019-05-15 Univ Manchester Biomarkers and uses thereof
CN110229894B (zh) * 2019-05-21 2020-09-08 武汉大学 一种基因组合及其在制备预测接受免疫检查点抑制剂治疗患者预后的试剂中的应用
WO2020252456A1 (en) 2019-06-14 2020-12-17 The Trustees Of Columbia University In The City Of New York Nt5c2 inhibitors for the treatment of chemotherapy-resistant acute lymphoblastic leukemia
US11705226B2 (en) 2019-09-19 2023-07-18 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
CN120866510A (zh) 2019-08-12 2025-10-31 雷杰纳荣制药公司 巨噬细胞刺激1受体(mst1r)变体及其用途
WO2021072280A1 (en) * 2019-10-09 2021-04-15 The University Of North Carolina At Chapel Hill Dna copy number alterations (cnas) to determine cancer phenotypes
CN110927389B (zh) * 2019-11-29 2021-07-16 中国科学院苏州生物医学工程技术研究所 一种癌症生物标志物、用途
CN121472194A (zh) 2020-01-23 2026-02-06 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
CN110923329B (zh) * 2020-02-06 2020-05-12 至本医疗科技（上海）有限公司 Fgfr4点突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
CN111269979A (zh) * 2020-02-06 2020-06-12 至本医疗科技（上海）有限公司 Arid1b基因变异在预测肺腺癌患者对免疫检查点抑制剂疗法敏感性中的应用
US20230193399A1 (en) * 2020-05-21 2023-06-22 Astrazeneca Ab Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma
TWI788188B (zh) * 2020-06-09 2022-12-21 南韓商阿特根公司 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
JP7622088B2 (ja) 2020-08-07 2025-01-27 アルテオジェン・インコーポレイテッド 組換えヒアルロニダーゼの生産方法
CN112143810B (zh) * 2020-09-29 2023-11-21 南方医科大学中西医结合医院 一组用于预测癌症免疫治疗效果的基因标志物及其应用
WO2022140387A1 (en) * 2020-12-22 2022-06-30 Ifm Due, Inc. Methods of treating cancer
WO2022135402A1 (zh) * 2020-12-24 2022-06-30 信达生物制药(苏州)有限公司 Pd-l1和/或mhc-2生物标记物在预测肺癌患者治疗疗效中的用途
KR102371762B1 (ko) * 2020-12-29 2022-03-07 중앙대학교 산학협력단 Brca1 매개 nsd2 유비퀴틴화를 통한 세포 분화 및 세포사멸 조절 용도
CN113005146A (zh) * 2021-03-10 2021-06-22 香港理工大学深圳研究院 一种重组质粒及其构建方法、重组影像系统与应用
EP4308159A4 (en) * 2021-03-19 2025-02-19 Topalliance Biosciences Inc. METHOD OF TREATMENT OF UROTHELIAL CARCINOMA
WO2022245692A1 (en) * 2021-05-19 2022-11-24 Merck Sharp & Dohme Llc Treatment of cancer patients with setd2 biomarker alteration with a pd-1 antagonist
JP7806990B2 (ja) * 2021-08-10 2026-01-27 国立大学法人 新潟大学 内胚葉嚢胞の悪性化に関連する遺伝子の検出方法
WO2023049859A1 (en) * 2021-09-24 2023-03-30 The Regents Of The University Of California Methods to predict the efficacy of neoadjuvant anti-pd-1 therapy in resectable oral-cavity squamous cell carcinoma and target post-surgical relapses
CN113981080A (zh) * 2021-10-15 2022-01-28 复旦大学附属肿瘤医院 晚期三阴性乳腺癌铂类治疗敏感性的预测指标生成分析方法
US20250019770A1 (en) * 2021-11-12 2025-01-16 Foundation Medicine, Inc. Circulating tumor dna fraction and uses thereof
CN114213542B (zh) * 2021-12-24 2023-06-23 郑州大学第三附属医院(河南省妇幼保健院) Cps-i抗体及其用途
US20250146078A1 (en) * 2022-02-11 2025-05-08 Foundation Medicine, Inc. Use of tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy effectiveness in cancer treatment
EP4515000B1 (en) * 2022-04-26 2026-04-01 F. Hoffmann-La Roche AG Methods and systems for predicting cancer therapy response
CN114736967B (zh) * 2022-05-07 2024-06-11 北京大学肿瘤医院 预测免疫检查点抑制剂疗法原发耐药的标志物及方法
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
EP4361288A1 (en) * 2022-10-25 2024-05-01 Fundación Instituto de Investigación Sanitaria De Santiago de Compostela (FIDIS) Personalized immunotherapy in renal carcinoma
CN115449555B (zh) * 2022-10-26 2023-10-13 山东大学 Adgra2作为乳腺癌化疗疗效和预后评价生物标志物的应用
CN116449009B (zh) * 2023-01-30 2026-05-08 上海秤信生物科技有限公司 预测肺癌三期患者的免疫新辅助疗效的自身抗体标志物
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
BRPI0012196B8 (pt) 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
AU2003259294A1 (en) 2002-07-30 2004-02-16 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
KR101444717B1 (ko) 2003-07-02 2014-09-26 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
ES2374603T3 (es) 2005-01-06 2012-02-20 Novo Nordisk A/S Agentes de unión a kir y procedimientos de uso de los mismos.
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
SI2195017T1 (sl) 2007-10-01 2015-01-30 Bristol-Myers Squibb Company Človeška protitelesa, ki vežejo mezotelin in njihova uporaba
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
NO2504364T3 (he) 2009-11-24 2018-01-06
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
BR112013012138B1 (pt) 2010-11-22 2022-02-22 Innate Pharma Sa Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
WO2012122444A1 (en) 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
PT2760471T (pt) 2011-09-30 2017-03-22 Dana Farber Cancer Inst Inc Péptidos terapêuticos
SI2776032T1 (sl) 2011-11-09 2018-12-31 Bristol-Myers Squibb Company Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesom
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
KR101549637B1 (ko) 2012-06-08 2015-09-03 국립암센터 신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
LT2904011T (lt) 2012-10-02 2017-11-10 Bristol-Myers Squibb Company Anti-kir antikūnų ir anti-pd-1 antikūnų derinys, akirtas vėžio gydymui
WO2014151006A2 (en) * 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
NZ629816A (en) 2013-03-15 2017-07-28 Dana Farber Cancer Inst Inc Therapeutic peptides
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
CN106029694A (zh) 2013-12-06 2016-10-12 达纳-法伯癌症研究院公司 治疗性肽
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
SG10201805674YA (en) * 2014-01-02 2018-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
EP4098278A1 (en) * 2014-11-13 2022-12-07 The Johns Hopkins University Checkpoint blockade and microsatellite instability
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
WO2016176504A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
MX2018007295A (es) 2016-01-11 2019-03-28 Armo Biosciences Inc Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN111385767A (zh) 2016-02-02 2020-07-07 华为技术有限公司 确定发射功率的方法、用户设备和基站
CN109476731A (zh) * 2016-02-29 2019-03-15 基础医药有限公司 治疗癌症的方法
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
EP3523451A1 (en) * 2016-10-06 2019-08-14 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2019075468A1 (en) * 2017-10-15 2019-04-18 Bristol-Myers Squibb Company TUMOR TREATMENT METHODS

Also Published As

Publication number Publication date
MA50056A (fr) 2020-02-05
CN110494450A (zh) 2019-11-22
JP2020512982A (ja) 2020-04-30
IL325195A (he) 2026-02-01
CA3058175A1 (en) 2018-10-04
US20210101980A1 (en) 2021-04-08
MX2019010958A (es) 2019-10-17
EP3601355A1 (en) 2020-02-05
JP2024096701A (ja) 2024-07-17
JP7458188B2 (ja) 2024-03-29
AU2018243754A1 (en) 2019-10-17
MX2024007719A (es) 2024-09-10
SG11201908396PA (en) 2019-10-30
IL313939A (he) 2024-08-01
IL269026B2 (he) 2024-12-01
BR112019019795A2 (pt) 2020-04-22
US20230295737A1 (en) 2023-09-21
AU2018243754B2 (en) 2025-04-10
IL269026B1 (he) 2024-08-01
SG10202110594UA (en) 2021-11-29
KR20190133213A (ko) 2019-12-02
AU2025205056A1 (en) 2025-07-24
IL269026A (he) 2019-10-31
KR102775647B1 (ko) 2025-03-06
WO2018183928A1 (en) 2018-10-04
KR20250036268A (ko) 2025-03-13
US20250059610A1 (en) 2025-02-20
IL313939B1 (he) 2026-01-01

Similar Documents

Publication Publication Date Title
IL290149A (he) טיפול משולב לטיפול בסרטן
SG11202104356VA (en) Bt1718 for use in treating cancer
IL263678B (he) תרכובות לשימוש בטיפול בסרטן השד +ar
IL280899B (he) תרכובות הטרוציקליות להדמייה וטיפול בסרטן ושיטות לשימוש בהן
PL3431105T3 (pl) Kompozycja lecznicza do leczenia raka
IL271221A (he) נוגדנים קושרי il-1בטא לשימוש בטיפול בסרטן
IL268479A (he) נוגדנים נגד pd-1 לטיפול בסרטן הריאה
IL276808A (he) תכשירים ושיטות לטיפול בסרטן
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
IL255060A0 (he) טיפול משולב לטיפול בסרטן
SG11201605296SA (en) Compounds and compositions for treating her2 positive tumors
IL277861A (he) נוגדנים ספציפיים ל axl לטיפול בסרטן
SI4339615T1 (sl) Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
IL267675A (he) שיטה לטיפול בסרטן מתקדם המבטא her2
IL254842B (he) תכשירים טיפוליים ושיטות לשימוש בטיפול בסרטן
IL247436A0 (he) תכשירים ושיטות לטיפול בגידולים שמבטאים בהפרזה her2/neu
IL281439A (he) טיפול משולב לטיפול בסרטן הדם
SG11202106295WA (en) Compositions and methods for cancer therapy
PL3253208T3 (pl) Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
IL280830A (he) תצמידים לשימוש בשיטות לטיפול בסרטן
IL279277A (he) טיפול משולב תוך-גופי מבוקר לטיפול בסרטן
IL268416A (he) צירופים רוקחיים לטיפול בסרטן
IL253533A0 (he) אנטיהיסטמין לשימוש בטיפול בסרטן השד
ZA201902951B (en) Nutritional composition for use in therapy of cancer patients
ZA202107993B (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors